Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a diagnosis of ulcerative colitis established at least 3 months prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report.~2. Has moderately to severely active ulcerative colitis as determined by a Mayo score of 6 to 12 with an endoscopic subscore greater than or equal to \>=2 within 14 days prior to the randomization.~3. Has evidence of ulcerative colitis proximal to the rectum (\>=15 centimeter \[cm\] of involved colon).~4. With extensive colitis (up to the hepatic flexure) or pancolitis of \>8 years duration or left-sided colitis of \>12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial screening visit (may be performed during the Screening Period).~5. The participant:~   1. Has had previous treatment with tumor necrosis factor- alpha (TNF-alpha) antagonists without documented clinical response to treatment (example, due to lack of response \[primary nonresponders\], loss of response, or intolerance \[secondary nonresponders\]), or~  2. Has previously used a TNF-alpha antagonists (except adalimumab), and discontinued its use due to reasons other than safety, or~  3. Is naïve to TNF-alpha antagonist therapy but is failing current treatment (example, corticosteroids, 5-aminosalicylate \[5-ASA\], or immunomodulators).~Exclusion Criteria:~1. Clinical evidence of abdominal abscess or toxic megacolon at Screening.~2. Has had an extensive colonic resection, subtotal or total colectomy.~3. Has had ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.~4. Has a diagnosis of Crohn's colitis or indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis.~5. Has received any of the following for the treatment of underlying disease within 30 days of randomization:~   1. Non-biologic therapies (example, cyclosporine, tacrolimus, thalidomide) other than those specifically listed in Section Permitted Medications For Treatment of UC.~  2. An approved non-biologic therapy in an investigational protocol.~6. Has received any investigational or approved biologic or biosimilar agent within 60 days or 5 half lives prior to the screening (whichever is longer).~7. Has previously received natalizumab, efalizumab, adalimumab, AMG-181, anti-mucosal addressin cell adhesion molecule-1 antibodies, or rituximab.~8. Has previously received vedolizumab.~9. Has history or evidence of adenomatous colonic polyps that have not been removed, or colonic mucosal dysplasia.~10. Evidence of an active infection during Screening.~11. Evidence of, or treatment for, Clostridium difficile (C. difficile) or other intestinal pathogen within 28 days prior to the 1st dose of study drug.~12. Has chronic hepatitis B virus (HBV) infection\* or chronic hepatitis C virus (HCV) infection (\* HBV immune participants, ie, being hepatitis B surface antigen \[HBsAg\], may participate).~13. Has active or latent TB, regardless of treatment history.~14. Has used a topical (rectal) treatment with (5-ASA) or corticosteroid enemas/suppositories within 2 weeks of the administration of the 1st dose of study drug.~15. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist prior to the administration of the first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vedolizumab IV 300 mg (Type: EXPERIMENTAL): Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
- Adalimumab SC 160/80/40 mg (Type: ACTIVE_COMPARATOR): Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete